In terms of treatment options when genomic data are unavailable, erlotinib has been shown to significantly prolong PFS and OS compared with placebo irrespective of EGFR mutation status both as switch maintenance therapy following conventional chemotherapy and in patients with NSCLC after failure of first- or second-line chemotherapy 14,65. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.